Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Revise Dyslipidemia Drug Development Guideline for 1st Time in 30 Years
February 25, 2021
- 4 APIs/9 Products Excluded from Kobayashi Kako Biz Suspension for Medical Needs
February 24, 2021
- MHLW Not Discussing Single-Dose Use of COVID-19 Vaccine: Minister
February 24, 2021
- Incyte’s Pemigatinib Clears PAFSC, March Approval Likely
February 24, 2021
- LDP COVID-19 Project Team to Compile Proposal on Single Vaccine Dose
February 24, 2021
- Orphan Status Granted to Novo’s Concizumab, Eisai’s E7090 and More
February 24, 2021
- LDP to Set Up Project Team to Strengthen Pharma Sector, Eyes Proposal in May
February 22, 2021
- Whether to Get COVID-19 Vaccines Up to Individuals to Decide: Govt
February 22, 2021
- First Possible Adverse Reactions from Pfizer Vaccine Reported in Japan
February 22, 2021
- Up to 1.17 Million Vaccine Doses to Be Shipped for HCPs in First Half of March
February 22, 2021
- Govt Plans Ticket Barcode Scan for New Vaccination Tracking System
February 18, 2021
- Japan Might Reconsider Vaccine Use for Kids under Age 16 If Data Obtained
February 18, 2021
- Celgene’s CAR-T Liso-Cel Now in Line for Possible March Approval in Japan
February 18, 2021
- Japan Launches COVID-19 Vaccination Program
February 18, 2021
- MHLW Hints It Might Take 1 Year for Kobayashi Kako to Resume Operations
February 17, 2021
- COVID-19 Vaccine Being Rolled Out for 40,000 Healthcare Workers in Japan
February 17, 2021
- Pregnant Women Not Urged to “Make Efforts” to Get COVID-19 Vaccines
February 16, 2021
- Chugai’s Blood-Based Genomic Profiling Test Now in Line for March OK
February 16, 2021
- PAFSC Minutes for Pfizer Vaccine Review Due Out around Feb. 26
February 16, 2021
- 17 Firms Get Approval for Cymbalta Generics, June Listing Eyed
February 16, 2021
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…